Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.

Garton AJ, Seibel S, Lopresti-Morrow L, Crew L, Janson N, Mandiyan S, Trombetta ES, Pankratz S, LaVallee TM, Gedrich R.

Mol Cancer Ther. 2017 Apr;16(4):671-680. doi: 10.1158/1535-7163.MCT-16-0676. Epub 2017 Jan 30.

2.

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R.

Clin Cancer Res. 2017 May 15;23(10):2565-2574. doi: 10.1158/1078-0432.CCR-16-2152. Epub 2016 Nov 4.

3.

Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.

Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP.

Immunotherapy. 2016 Jun;8(7):767-74. doi: 10.2217/imt-2016-0040. Review.

PMID:
27349976
4.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1.

5.

Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.

LaVallee TM, Alvarado D, Garton AJ, Trombetta ES, Gedrich R, McMahon G.

Crit Rev Oncog. 2015;20(5-6):485-508. doi: 10.1615/CritRevOncog.v20.i5-6.170. Review.

PMID:
27279243
6.

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR.

Clin Cancer Res. 2015 Feb 15;21(4):701-11. doi: 10.1158/1078-0432.CCR-14-0303. Epub 2014 Sep 11.

7.

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.

Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP.

Clin Cancer Res. 2015 Feb 15;21(4):693-700. doi: 10.1158/1078-0432.CCR-14-0265. Epub 2014 Sep 10.

8.

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M.

Clin Cancer Res. 2013 Feb 15;19(4):909-19. doi: 10.1158/1078-0432.CCR-12-2258. Epub 2013 Feb 12.

9.

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.

Macpherson IR, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TR.

Eur J Cancer. 2013 Mar;49(4):782-9. doi: 10.1016/j.ejca.2012.09.036. Epub 2012 Oct 22.

PMID:
23099006
10.

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.

Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F.

Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

11.

High-throughput mass spectrometry screening for inhibitors of phosphatidylserine decarboxylase.

Forbes CD, Toth JG, Ozbal CC, Lamarr WA, Pendleton JA, Rocks S, Gedrich RW, Osterman DG, Landro JA, Lumb KJ.

J Biomol Screen. 2007 Aug;12(5):628-34. Epub 2007 May 3.

PMID:
17478478
12.

Antitumor activity of sorafenib in FLT3-driven leukemic cells.

Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.

Leukemia. 2007 Mar;21(3):439-45. Epub 2007 Jan 4.

PMID:
17205056
13.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

14.

Translocation of TRAF proteins regulates apoptotic threshold of cells.

Arch RH, Gedrich RW, Thompson CB.

Biochem Biophys Res Commun. 2000 Jun 16;272(3):936-45.

PMID:
10860854
15.

Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death.

Arch RH, Gedrich RW, Thompson CB.

Genes Dev. 1998 Sep 15;12(18):2821-30. Review. No abstract available.

16.

Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB.

Mol Cell Biol. 1997 Mar;17(3):1535-42.

17.

A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors.

Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM, Thompson CB.

EMBO J. 1996 Jun 3;15(11):2685-94.

18.
19.
20.
22.

Supplemental Content

Loading ...
Support Center